Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study
Journal of Clinical Oncology, 11/05/09

Finn RS et al. – HER2 bECD does not predict lapatinib benefit in patients with HER2-negative MBC. Changes in ECD status correlates with patient outcome regardless of treatment given. Measuring HER2 ECD is not currently recommended for predicting benefit to lapatinib.

Methods

Patients (n = 579) with newly diagnosed metastatic breast cancer (MBC) randomly assigned to paclitaxel with placebo or lapatinib
HER2 status was determined centrally
ECD was centrally measured by enzyme linked immunoassay in available samples at baseline (b; n = 472), week 9, and every 12 weeks thereafter
Results correlated to ORR and PFS

Results

Elevated baseline ECD (bECD) levels ( 16 ng/mL) did not predict HER2 tumor status
In HER2-negative tumors, elevated bECD not correlated with improved efficacy for lapatinib plus paclitaxel versus placebo plus paclitaxel
ECD levels tended to decrease over time when bECD elevated
ECD conversion from low to high associated with worse PFS
Converting from high to low associated with better PFS
Consistently low ECD level had better PFS than consistently elevated ECD
Associations found to be independent of lapatinib

<< Previous
Higher hospital spending linked to better outcomes

Next >>
Fluorouracil, epirubicin, and cyclophosphamide with either...